Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (USD)
Sales 2018 73,2 M
EBIT 2018 -4,76 M
Net income 2018 -13,6 M
Debt 2018 123 M
Yield 2018 -
Sales 2019 98,0 M
EBIT 2019 6,85 M
Net income 2019 -6,28 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 4,55x
Capi. / Sales2019 2,14x
Capitalization 210 M
More Financials
Company
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products.It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets.The company was founded by Jane E. Hager in... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
06/21TELIGENT : Announces FDA Approval of Fluocinonide Gel, 0.05%
AQ
06/20TELIGENT : Announces FDA Approval of Fluocinonide Gel, 0.05%
AQ
06/20TELIGENT : Announces FDA Approval of Fluocinonide Gel, 0.05%
AQ
06/20Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Sto..
AC
06/15TELIGENT : shares pop on FDA approval of its topical corticosteroid ointment, Di..
AQ
06/14TELIGENT : Scores Big on Latest FDA Approval
AQ
06/14TELIGENT : Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%
AQ
06/14TELIGENT : Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%
AQ
06/13TELIGENT : Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%
AQ
06/06TELIGENT : Announces Closing Of $25 Million Secured Credit Facility
AQ
More news
Sector news : Pharmaceuticals - NEC
11:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07:38aRoche to Appoint James Sabry as Head of Partnering
DJ
06/21LONDON MARKETS: FTSE 100 Drops As Oil Shares Extend Losses; Pound Rallies On ..
DJ
06/21Canada sets October start for legal recreational marijuana sales
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,30 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Damian Finio Chief Financial Officer & Secretary
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI210
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862